Twenty years ago, the completion of the Human Genome Project felt like a starting gun. Not a finish line. The landmark paper by Francis Collins, Michael Morgan, and Aristides Patrinos published in PLoS Biology in 2003 laid out the project’s legacy and its unfinished business with unusual candor. It didn’t just celebrate the sequencing of 3 billion base pairs of human DNA. It asked what comes next—and whether the scientific community was ready for it.
The short answer: it wasn’t. Not entirely.
The Human Genome Project (HGP), completed in April 2003 after 13 years and roughly $2.7 billion in public funding, remains the largest coordinated biological research effort in history. Collins and his co-authors argued that the project’s real value wasn’t the sequence itself but the infrastructure it created—open-access databases, new sequencing technologies, bioinformatics tools, and an international culture of data sharing that simply didn’t exist before. That infrastructure has since underpinned nearly every major advance in genomics, from CRISPR gene editing to mRNA vaccines.
But the paper is also remarkably honest about what the genome sequence didn’t immediately deliver. The authors outlined a vision structured around three broad themes: genomics to biology, genomics to health, and genomics to society. Each carried ambitious goals. And each came with caveats about how far the field still had to go.
On the biology front, Collins et al. emphasized that having the sequence was only the first step toward understanding gene function. Identifying all the protein-coding genes—estimated at the time between 20,000 and 25,000—was one thing. Figuring out what the vast stretches of non-coding DNA actually do was another problem entirely. The paper predicted that understanding gene regulation, epigenetics, and the functional elements buried in so-called “junk DNA” would consume the field for decades. That prediction held up. Projects like ENCODE, launched in 2003 by the National Human Genome Research Institute, have since cataloged millions of functional elements across the genome, revealing that at least 80 percent of the genome has some biochemical activity—though what counts as “functional” remains hotly debated.
The health implications were where the paper’s optimism ran highest, and where reality has been most complicated. Collins and colleagues envisioned a future in which genomic information would enable personalized medicine: drugs tailored to individual genetic profiles, early detection of disease risk, pharmacogenomics guiding prescriptions. Some of that has materialized. Targeted cancer therapies like imatinib (Gleevec) for chronic myeloid leukemia were already proving the concept when the paper was published. Today, tumor genomic profiling is standard practice in oncology, and the FDA has approved dozens of drugs with companion diagnostics tied to specific genetic markers.
Still, the broader promise of genomic medicine has been slower to arrive than many anticipated. Polygenic risk scores—which aggregate the effects of thousands of genetic variants to predict disease susceptibility—are gaining traction but remain controversial. A 2022 study in Nature Medicine found that polygenic scores for conditions like coronary artery disease and type 2 diabetes have meaningful predictive power but don’t yet outperform traditional clinical risk factors in most populations. And they perform worse in non-European populations, a direct consequence of the lack of diversity in early genomic studies—something Collins et al. flagged as a concern two decades ago.
That diversity gap persists. As of 2023, roughly 86 percent of participants in genome-wide association studies are of European descent, according to data tracked by the GWAS Catalog. Efforts like the All of Us Research Program, which aims to sequence one million diverse genomes, are trying to close the gap. Progress has been real but incremental.
The societal dimensions of the HGP may be the paper’s most prescient section. Collins and his co-authors devoted significant attention to the ethical, legal, and social implications (ELSI) of genomic research—a component that received roughly 5 percent of the HGP’s total budget, a first for a large-scale science project. They warned about genetic discrimination, privacy risks, and the potential for genomic information to deepen existing inequalities.
Those warnings proved well-founded. The Genetic Information Nondiscrimination Act (GINA) wasn’t signed into law until 2008, five years after the genome’s completion. And GINA has gaps—it doesn’t cover life insurance, disability insurance, or long-term care insurance, leaving significant exposure for individuals whose genomic data reveals elevated risk for certain conditions. The rise of direct-to-consumer testing through companies like 23andMe has made these questions more urgent. When 23andMe filed for bankruptcy protection in March 2025, as reported by Wired, concerns about the fate of its 15 million customers’ genetic data underscored exactly the kind of scenario the original HGP architects worried about.
So where does this leave us? The HGP’s most lasting contribution may not be any single discovery but rather the principle that large-scale biological data should be freely accessible. The Bermuda Principles, established in 1996 during the project, mandated that all human sequence data be deposited in public databases within 24 hours of generation. That open-access ethos shaped how science operates today, influencing everything from the rapid sharing of SARS-CoV-2 sequences during the pandemic to the open publication of AlphaFold’s protein structure predictions by DeepMind.
The Collins, Morgan, and Patrinos paper reads differently now than it did in 2003. Some of its predictions were too optimistic on timelines. Others were remarkably accurate about the challenges ahead. What stands out most is the framework it proposed: that sequencing the genome was a means, not an end. The hard work—translating raw sequence into medical insight, ensuring equitable access, protecting individual privacy—was always going to take longer than the sequencing itself.
Two decades on, that work continues. The genome is read. Understanding it is another matter entirely.
WebProNews is an iEntry Publication